Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer

James Laird; Jonathan Leventhal; Jane Kanowitz; Shari Damast

doi:10.1016/j.prro.2021.06.001

Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer

Pract Radiat Oncol. 2021 Nov-Dec;11(6):448-452. doi: 10.1016/j.prro.2021.06.001. Epub 2021 Jun 23.

Authors

James Laird¹, Jonathan Leventhal², Jane Kanowitz³, Shari Damast⁴

Affiliations

¹ Department of Therapeutic Radiology.
² Department of Dermatology.
³ Department of Medical Oncology.
⁴ Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: shari.damast@yale.edu.

PMID: 34157449
DOI: 10.1016/j.prro.2021.06.001

Abstract

A case is descibed of radiation recall dermatitis in a patient treated with adjuvant radiation therapy followed by capecitabine for triple negative breast cancer with residual disease after neoadjuvant chemotherapy.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Breast Neoplasms* / drug therapy
Breast Neoplasms* / radiotherapy
Capecitabine / adverse effects
Chemotherapy, Adjuvant
Female
Humans
Neoadjuvant Therapy / adverse effects
Neoplasm, Residual
Radiodermatitis* / chemically induced
Triple Negative Breast Neoplasms* / drug therapy

Substances

Capecitabine